Dynamics of Chronic Myeloid Leukemia Under Imatinib Treatment: A Study of Resistance Development

被引:0
|
作者
Badralexi, Irina [1 ]
Bordei, Ana-Maria [2 ]
Halanay, Andrei [3 ]
Radulescu, Ileana Rodica [1 ]
机构
[1] Natl Univ Sci & Technol, Politehn Bucharest, Dept Math Methods & Models, Bucharest 060042, Romania
[2] Natl Inst Aerosp Res Elie Carafoli INCAS Bucharest, Bucharest 061126, Romania
[3] Natl Univ Sci & Technol, Politehn Bucharest, Dept Math & Informat, Bucharest 060042, Romania
关键词
chronic myeloid leukemia; asymmetric division; immune system; imatinib; delay differential equations; MATHEMATICAL-MODEL; DELAY SYSTEMS; STABILITY; HEMATOPOIESIS; BIOLOGY; CELLS;
D O I
10.3390/math12243937
中图分类号
O1 [数学];
学科分类号
0701 ; 070101 ;
摘要
Chronic myeloid leukemia (CML) is a hematological disorder characterized by the abnormal proliferation of leukemic cells. This study aims to model the dynamics of leukemic and healthy cell populations in CML, considering the role of the immune system and the effects of treatment with Imatinib. The model also addresses the development of treatment resistance in cells, following the Goldie-Coldman hypothesis. We employ a system of delay differential equations to simulate the interactions between leukemic cells, healthy cells, and the immune system under treatment. The results provide insights into the dynamic balance between leukemic cells, healthy cells, and immune responses, and the impact of developing resistance on treatment outcomes.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Treatment selection after imatinib resistance in chronic myeloid leukemia
    Elias Jabbour
    Jorge Cortes
    Hagop Kantarjian
    Targeted Oncology, 2009, 4 : 3 - 10
  • [2] Treatment selection after imatinib resistance in chronic myeloid leukemia
    Jabbour, Elias
    Cortes, Jorge
    Kantarjian, Hagop
    TARGETED ONCOLOGY, 2009, 4 (01) : 3 - 10
  • [3] Development of a test to predict resistance to imatinib mesylate in the treatment of chronic myeloid leukemia.
    Schultheis, B
    Fidanis, E
    Mahon, FX
    Apperley, JF
    Goldman, JM
    Melo, JV
    BLOOD, 2003, 102 (11) : 71A - 72A
  • [4] Treatment of chronic myeloid leukemia with imatinib: IRIS study
    Saußele S.
    Nitschmann S.
    Der Internist, 2017, 58 (11): : 1220 - 1221
  • [5] Factors of imatinib resistance in chronic myeloid leukemia
    Kajtar, B.
    Alpar, D.
    Toth, J.
    Laszlo, R.
    Jakso, R.
    Kereskai, L.
    Nagy, Z.
    Pajor, L.
    BLOOD REVIEWS, 2007, 21 : S78 - S78
  • [6] Treatment of chronic myeloid Leukemia with Imatinib IRIS-Study
    Saussele, S.
    Nitschmann, S.
    INTERNIST, 2017, 58 (11): : 1220 - 1221
  • [7] Successful Pregnancy in a Patient with Chronic Myeloid Leukemia under Treatment with Imatinib
    Tsuzuki, Motohiro
    Inaguma, Youko
    Handa, Kousuke
    Hasegawa, Akio
    Yamamoto, Yukiya
    Watanabe, Masato
    Mizuta, Syuichi
    Maruyama, Fumio
    Okamoto, Masataka
    Emi, Nobuhiko
    INTERNAL MEDICINE, 2009, 48 (16) : 1433 - 1435
  • [8] Treatment of Chronic Phase Chronic Myeloid Leukemia with Imatinib
    Ganesan, Prasanth
    Rajendranath, Rejiv
    Kandakumar, Vignesh
    Sagar, Tenali Gnana
    INDIAN JOURNAL OF PEDIATRICS, 2015, 82 (03): : 235 - 239
  • [9] Treatment of Chronic Phase Chronic Myeloid Leukemia with Imatinib
    Prasanth Ganesan
    Rejiv Rajendranath
    Vignesh Kandakumar
    Tenali Gnana Sagar
    The Indian Journal of Pediatrics, 2015, 82 : 235 - 239
  • [10] Chronic myeloid leukemia and its treatment with imatinib
    Treuil, Pascal
    ACTUALITES PHARMACEUTIQUES, 2008, 47 (473): : 25 - 30